Hints and tips:
...As well as proceeds from its Covid products, Pfizer has also benefited from the spin-off of its Upjohn generics business, which combined with Mylan to form Viatris in late 2020....
...In 2020, Pfizer spun off its generics business Upjohn, combining it with Mylan to form Viatris, while Johnson & Johnson, GSK, Pfizer and Novartis have all shed their consumer health businesses selling over-the-counter...
...The state of Michigan is spending between $160,000 and $210,000 for every job created or retained through GM’s new investments, said Tim Bartik, senior economist at the WE Upjohn Institute for Employment...
...Results and forecasts exclude its Upjohn unit, as Pfizer closed the transaction to merge the generics business with Mylan during the quarter....
...The Boston-based biotech company said that it was pleased with the decision....
...GSK and Pfizer are uniting and spinning off their consumer health divisions, which sell over-the-counter products, while Pfizer is in the process of trying to combine its generics business Upjohn with the...
...Here, however, Pfizer is spinning off Upjohn and then combining it with all of Mylan. Pfizer shareholders will own 57 per cent of the new company, with Mylan shareholders owning the rest....
...Sales of branded drugs at Pfizer outpaced revenues from Upjohn, its off-patent business in the country, climbing 32 per cent year on year in the quarter compared with a 2 per cent increase for the generics...
...By bringing Mylan’s growth assets to Upjohn’s growth markets, we will create a financially strong company with true global reach”....
...company GlaxoSmithKline....
...Multinational pharmaceutical companies are facing a tricky transition in China, where regulatory reforms have led to price cuts and greater competition from local companies, forcing them to shift from a...
...The company is preparing to launch breast cancer immunotherapy Ibrance, sales of which soared 25 per cent globally in the first quarter, in China....
...The academics needed an industrial partner, but Mr Curstedt says that Pharmacia, a Swedish drugs company which has since become part of Pfizer, felt “the sales were too small and the marketing costs too...
...The sale of Meda risks a further hollowing out of Sweden’s pharmaceuticals sector, which in the past two decades has seen Pharmacia bought by Pfizer of the US and Astra merged with Zeneca of the UK....
...to Upjohn of the US and then Pfizer....
...When Pfizer took the company over in 2003, it had long ceased to have its headquarters in Sweden, with it having moved to first the UK and then the US as part of a 1995 merger with Upjohn of the US....
...Mr Heldin said foreign takeovers of both Astra and Pharmacia, which was first bought in 1995 by Upjohn of the US, had been “very bad” for Sweden....
...The company declined to comment on the Pharmacia deal....
...Not only was his name omitted from the document but the company had reported him to the FDA for carrying out unauthorised human trials....
...He said the commitments offered by Pfizer “fly in the face of what they have done when they have acquired companies in the past”, pointing to job losses after takeovers of Pharmacia and Warner Lambert....
...Pfizer has a history of big acquisitions, such as its $68bn takeover of Wyeth in 2009 and its $56bn deal with Pharmacia in 2002....
...Work on the drug dates back to the late 1980s, when Steven Brickner, a chemist at the pharmaceutical company Upjohn of the US, heard presentations on a new experimental class of anti-bacterial medicines...
...Mr Borg had earlier criticised Pfizer’s behaviour after taking over Swedish group Pharmacia a decade ago....
...“There is its acquisition of Warner-Lambert in 2000 in the US; Pharmacia in Sweden in 2003; and Wyeth in the US in 2000, and that led to deep cuts in the research facilities, it led to intellectual asset-stripping...
...Two years later, Hank McKinnell, Mr Steere’s replacement, launched a $60bn takeover of Pharmacia, securing drugs including Celebrex, then part of a promising class of new painkillers....
International Edition